APTO vs. CGTX, AVRO, SNTI, CRIS, QNCX, UPTD, LIFE, BCLI, TCRR, and ALGS
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Cognition Therapeutics (CGTX), AVROBIO (AVRO), Senti Biosciences (SNTI), Curis (CRIS), Quince Therapeutics (QNCX), TradeUP Acquisition (UPTD), aTyr Pharma (LIFE), Brainstorm Cell Therapeutics (BCLI), TCR2 Therapeutics (TCRR), and Aligos Therapeutics (ALGS). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences vs.
Aptose Biosciences (NASDAQ:APTO) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends, valuation and community ranking.
Cognition Therapeutics' return on equity of -51.42% beat Aptose Biosciences' return on equity.
Aptose Biosciences received 362 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 68.15% of users gave Aptose Biosciences an outperform vote while only 50.00% of users gave Cognition Therapeutics an outperform vote.
Aptose Biosciences has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 23.1% of Cognition Therapeutics shares are held by institutional investors. 10.9% of Aptose Biosciences shares are held by insiders. Comparatively, 20.6% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Aptose Biosciences presently has a consensus price target of $5.50, indicating a potential upside of 753.90%. Cognition Therapeutics has a consensus price target of $9.50, indicating a potential upside of 389.69%. Given Aptose Biosciences' higher probable upside, research analysts plainly believe Aptose Biosciences is more favorable than Cognition Therapeutics.
In the previous week, Cognition Therapeutics had 2 more articles in the media than Aptose Biosciences. MarketBeat recorded 8 mentions for Cognition Therapeutics and 6 mentions for Aptose Biosciences. Cognition Therapeutics' average media sentiment score of 0.75 beat Aptose Biosciences' score of 0.25 indicating that Cognition Therapeutics is being referred to more favorably in the news media.
Summary
Cognition Therapeutics beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptose Biosciences Competitors List
